Veracyte (VCYT) Expected to Announce Quarterly Earnings on Wednesday

Veracyte (NASDAQ:VCYT - Get Free Report) is expected to release its Q1 2025 earnings data after the market closes on Wednesday, May 7th. Analysts expect Veracyte to post earnings of $0.21 per share and revenue of $110.81 million for the quarter.

Veracyte (NASDAQ:VCYT - Get Free Report) last posted its earnings results on Monday, February 24th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.07. Veracyte had a positive return on equity of 3.02% and a negative net margin of 2.18%. The firm had revenue of $118.63 million for the quarter, compared to analysts' expectations of $110.73 million. During the same period in the previous year, the firm earned ($0.39) earnings per share. On average, analysts expect Veracyte to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Veracyte Price Performance

NASDAQ:VCYT traded up $0.64 during trading hours on Friday, hitting $30.35. The company had a trading volume of 1,748,178 shares, compared to its average volume of 871,750. The stock has a 50-day moving average price of $31.48 and a 200 day moving average price of $37.22. The company has a market capitalization of $2.37 billion, a PE ratio of -202.33 and a beta of 2.03. Veracyte has a 52 week low of $19.73 and a 52 week high of $47.32.

Analyst Upgrades and Downgrades

VCYT has been the topic of several research analyst reports. Stephens reiterated an "overweight" rating and set a $45.00 price target on shares of Veracyte in a research report on Wednesday, March 26th. Needham & Company LLC reissued a "buy" rating and issued a $51.00 target price on shares of Veracyte in a research report on Tuesday, February 25th. UBS Group lifted their price target on Veracyte from $46.00 to $49.00 and gave the company a "buy" rating in a research report on Tuesday, February 25th. Craig Hallum began coverage on Veracyte in a research note on Thursday, March 20th. They issued a "buy" rating and a $45.00 price target on the stock. Finally, StockNews.com lowered Veracyte from a "buy" rating to a "hold" rating in a research report on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, Veracyte presently has an average rating of "Moderate Buy" and an average target price of $42.60.

About Veracyte

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.